These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34580027)

  • 61. Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up.
    Barth DA; Sareban N; Lindner AK; Daller LAJ; Matzhold EM; Hutterer G; Smolle M; Mischinger J; Riedl JM; Seles M; Mannweiler S; Bauernhofer T; Pummer K; Pichler R; Zigeuner R; Schlenke P; Pichler M
    Urol Oncol; 2021 Oct; 39(10):736.e9-736.e16. PubMed ID: 34247906
    [TBL] [Abstract][Full Text] [Related]  

  • 62. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.
    Vermaat JS; Gerritse FL; van der Veldt AA; Roessingh WM; Niers TM; Oosting SF; Sleijfer S; Roodhart JM; Beijnen JH; Schellens JH; Gietema JA; Boven E; Richel DJ; Haanen JB; Voest EE
    Eur Urol; 2012 Oct; 62(4):685-95. PubMed ID: 22285764
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer.
    Sidana A; Kadakia M; Friend JC; Krane LS; Su D; Merino MJ; Srinivasan R
    Urol Oncol; 2017 Mar; 35(3):114.e9-114.e14. PubMed ID: 27914873
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy.
    Lee H; Kim YJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kwak C; Kim HH; Oh JJ; Lee SC; Hong SK; Lee SE; Byun SS;
    BMC Cancer; 2017 May; 17(1):364. PubMed ID: 28545466
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
    J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 68. On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study.
    Bolzacchini E; Pinotti G; Bertù L; Verusio C; Galli L; Mumoli N; Barbara C; Danova M; Bregni M; Artale S; Rossini C; Nigro O; Antonuzzo A; Derosa L; Torchio M; Barzaghi S; Ricci I; Suter M; Ballerio A; Vallini I; Dentali F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e145-e156. PubMed ID: 31889670
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
    Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
    Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
    Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
    Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
    PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Baseline Edmonton Symptom Assessment System and survival in metastatic renal cell carcinoma.
    Graham J; Gingerich J; Lambert P; Alamri A; Czaykowski P
    Curr Oncol; 2018 Aug; 25(4):e319-e323. PubMed ID: 30111978
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comprehensive analysis and validation of contemporary survival prognosticators in Korean patients with metastatic renal cell carcinoma treated with targeted therapy: prognostic impact of pretreatment neutrophil-to-lymphocyte ratio.
    Koo KC; Lee KS; Cho KS; Rha KH; Hong SJ; Chung BH
    Int Urol Nephrol; 2016 Jun; 48(6):985-92. PubMed ID: 26946137
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
    Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
    Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
    Wang HK; Wan FN; Gu WJ; Zhu Y; Dai B; Shi GH; Zhang HL; Ye DW
    Oncotarget; 2016 Oct; 7(42):68943-68953. PubMed ID: 27661105
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
    Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
    Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Paraneoplastic elevation of serum alkaline phosphatase in renal cell carcinoma: incidence and implication on prognosis.
    Chuang YC; Lin AT; Chen KK; Chang YH; Chen MT; Chang LS
    J Urol; 1997 Nov; 158(5):1684-7. PubMed ID: 9334578
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma.
    Magera JS; Leibovich BC; Lohse CM; Sengupta S; Cheville JC; Kwon ED; Blute ML
    Urology; 2008 Feb; 71(2):278-82. PubMed ID: 18308103
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients.
    Pichler M; Hutterer GC; Stojakovic T; Mannweiler S; Pummer K; Zigeuner R
    Br J Cancer; 2013 Sep; 109(5):1123-9. PubMed ID: 23922109
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.
    Wood SL; Rogers M; Cairns DA; Paul A; Thompson D; Vasudev NS; Selby PJ; Banks RE
    Br J Cancer; 2010 Jun; 103(1):101-11. PubMed ID: 20531413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.